Statistics can kill: how Ebola treatment is being slowed by the drug trials process

The Ebola crisis brings into sharp contrast the importance of appropriate regulation for trials of new drugs. The “gold standard” in clinical research is the randomised trial, but the reliance on one particular measure of evidence arguably risks lives and may be holding back our efforts to defeat a disease which has sparked fear around the globe.

To read more click here or go to


Get the latest posts delivered to your mailbox:

Show Buttons
Share On Facebook
Share On Twitter
Share On Google Plus
Share On Linkdin
Contact us
Hide Buttons